잠시만 기다려 주세요. 로딩중입니다.

The emerging role of myeloid-derived suppressor cells in radiotherapy

Radiation Oncology Journal 2020년 38권 1호 p.1 ~ 10
Kang Chang-Hee, 정성윤, 송시열, 최은경,
소속 상세정보
 ( Kang Chang-Hee ) - University of Ulsan College of Medicine Asan Medical Center Asan Institute for Life Sciences
정성윤 ( Jeong Seong-Yun ) - University of Ulsan College of Medicine Asan Medical Center Asan Institute for Life Sciences
송시열 ( Song Si-Yeol ) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
최은경 ( Choi Eun-Kyung ) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology

Abstract


Radiotherapy (RT) has been used for decades as one of the main treatment modalities for cancer patients. The therapeutic effect of RT has been primarily ascribed to DNA damage leading to tumor cell death. Besides direct tumoricidal effect, RT affects antitumor responses through immune-mediated mechanism, which provides a rationale for combining RT and immunotherapy for cancer treatment. Thus far, for the combined treatment with RT, numerous studies have focused on the immune checkpoint inhibitors and have shown promising results. However, treatment resistance is still common, and one of the main resistance mechanisms is thought to be due to the immunosuppressive tumor microenvironment where myeloid-derived suppressor cells (MDSCs) play a crucial role. MDSCs are immature myeloid cells with a strong immunosuppressive activity. MDSC frequency is correlated with tumor progression, recurrence, negative clinical outcome, and reduced efficacy of immunotherapy. Therefore, increasing efforts to target MDSCs have been made to overcome the resistance in cancer treatments. In this review, we focus on the role of MDSCs in RT and highlight growing evidence for targeting MDSCs in combination with RT to improve cancer treatment.

키워드

Radiotherapy; Immune checkpoint inhibitors; Tumor microenvironment; Myeloid-derived suppressor cells

원문 및 링크아웃 정보

 

등재저널 정보